|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.00 GBX | +3.65% |
|
-0.70% | +22.41% |
| 06-05 | Avacta Group raises GBP9 million for bond repayments | AN |
| 06-05 | Avacta Therapeutics Raises GBP9 Million from Share Issue | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 3.64M | 2.94M | 9.65M | 23.25M | 113K | |||||
Total Revenues | 3.64M | 2.94M | 9.65M | 23.25M | 113K | |||||
Cost of Goods Sold, Total | 2.46M | 3.89M | 3.46M | 12M | - | |||||
Gross Profit | 1.17M | -947K | 6.19M | 11.24M | 113K | |||||
Selling General & Admin Expenses, Total | 7.32M | 8.14M | 11.23M | 16.86M | 12.05M | |||||
Stock-Based Compensation (IS) | 3.11M | 5.06M | 7.49M | 2.91M | 4.11M | |||||
R&D Expenses | 8.96M | 13.48M | 11.1M | 14.53M | 14.27M | |||||
Depreciation & Amortization - (IS) | 1.12M | 1.46M | 1.9M | 2.64M | 1.49M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | - | - | - | 1.03M | 16K | |||||
Other Operating Expenses, Total | 20.51M | 28.14M | 31.73M | 37.96M | 31.92M | |||||
Operating Income | -19.34M | -29.08M | -25.53M | -26.72M | -31.81M | |||||
Interest Expense, Total | -93K | -128K | -2.7M | -15.3M | -10.09M | |||||
Interest And Investment Income | 43K | 17K | 91K | 655K | 663K | |||||
Net Interest Expenses | -50K | -111K | -2.61M | -14.64M | -9.43M | |||||
Income (Loss) On Equity Invest. | -217K | - | -1.15M | -847K | -747K | |||||
Other Non Operating Income (Expenses) | - | - | -4.1M | 15.68M | 13M | |||||
EBT, Excl. Unusual Items | -19.6M | -29.19M | -33.4M | -26.52M | -28.98M | |||||
Merger & Related Restructuring Charges | - | - | -3.02M | -282K | - | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Asset Writedown | -1.74M | - | -5.22M | -512K | - | |||||
EBT, Incl. Unusual Items | -21.34M | -29.19M | -41.64M | -27.32M | -28.98M | |||||
Income Tax Expense | -2.45M | -2.82M | -2.1M | -2.37M | 444K | |||||
Earnings From Continuing Operations | -18.89M | -26.37M | -39.54M | -24.95M | -29.43M | |||||
Earnings Of Discontinued Operations | - | 58K | 351K | - | -23.41M | |||||
Net Income to Company | -18.89M | -26.32M | -39.19M | -24.95M | -52.84M | |||||
Net Income - (IS) | -18.89M | -26.32M | -39.19M | -24.95M | -52.84M | |||||
Net Income to Common Incl Extra Items | -18.89M | -26.32M | -39.19M | -24.95M | -52.84M | |||||
Net Income to Common Excl. Extra Items | -18.89M | -26.37M | -39.54M | -24.95M | -29.43M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.08 | -0.11 | -0.15 | -0.09 | -0.15 | |||||
Basic EPS - Continuing Operations | -0.08 | -0.11 | -0.15 | -0.09 | -0.09 | |||||
Basic Weighted Average Shares Outstanding | 226M | 249M | 255M | 273M | 345M | |||||
Net EPS - Diluted | -0.08 | -0.11 | -0.15 | -0.09 | -0.15 | |||||
Diluted EPS - Continuing Operations | -0.08 | -0.11 | -0.15 | -0.09 | -0.09 | |||||
Diluted Weighted Average Shares Outstanding | 226M | 249M | 255M | 273M | 345M | |||||
Normalized Basic EPS | -0.05 | -0.07 | -0.08 | -0.06 | -0.05 | |||||
Normalized Diluted EPS | -0.05 | -0.07 | -0.08 | -0.06 | -0.05 | |||||
Supplemental Items | ||||||||||
EBITDA | -18.45M | -27.61M | -24.34M | -24.62M | -30.37M | |||||
EBITA | -19.33M | -29.08M | -25.36M | -25.75M | -31.8M | |||||
EBIT | -19.34M | -29.08M | -25.53M | -26.72M | -31.81M | |||||
EBITDAR | -18.45M | -27.58M | -24.3M | -24.4M | -30.21M | |||||
Effective Tax Rate - (Ratio) | 11.49 | 9.66 | 5.05 | 8.68 | -1.53 | |||||
Current Domestic Taxes | - | - | - | - | - | |||||
Current Foreign Taxes | - | - | - | - | -1.82M | |||||
Total Current Taxes | -2.45M | -2.82M | -2.04M | -2.09M | -1.82M | |||||
Deferred Foreign Taxes | - | - | - | - | 2.27M | |||||
Total Deferred Taxes | - | - | -63K | -279K | 2.27M | |||||
Normalized Net Income | -12.25M | -18.25M | -20.87M | -16.58M | -18.11M | |||||
Interest on Long-Term Debt | 93K | 138K | 2.83M | 15.3M | 10.21M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | - | - | - | - | - | |||||
Research And Development Expense From Footnotes | 9.97M | 14.3M | 17.15M | 14.58M | 14.27M | |||||
Net Rental Expense, Total | 2K | 29K | 42K | 222K | 157K | |||||
Imputed Operating Lease Interest Expense | 1.04K | 15.86K | 28.08K | 519K | 357K | |||||
Imputed Operating Lease Depreciation | 961 | 13.14K | 13.92K | -297K | -200K | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 3.11M | 5.06M | 7.49M | 2.91M | 4.11M | |||||
Total Stock-Based Compensation | 3.11M | 5.06M | 7.49M | 2.91M | 4.11M |
- Stock Market
- Stocks
- AVCT Stock
- Financials Avacta Group Plc
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















